Hydralazine-Induced Vasculitis Causing Pulmonary-Renal Syndrome: Two Cases and a Literature Review
West Virginia Medical Journal · 01.06.2024 · 120 (2) · 16
DOI: 10.21885/wvmj.2024.09 ↗Kurz gefasst
Fachartikel in der Zeitschrift West Virginia Medical Journal, online erschienen am 01.06.2024. Verfasst von Mark Radow und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION Hydralazine has been used to treat hypertension for several decades, but its use has been limited due to side effects, principally drug-induced lupus. Nevertheless, prescriptions for hydralazine have increased in the last decade. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a less appreciated but more severe side effect of hydralazine use. Here we present two cases of pulmonary-renal syndrome due to hydralazine-induced ANCA-associated vasculitis and a medical literature review of this topic. This report underscores the importance of prompt recognition and treatment of this condition.
Zitieren
APA
Radow, M., MD, Morehead, R. S., & MD (2024). Hydralazine-Induced Vasculitis Causing Pulmonary-Renal Syndrome: Two Cases and a Literature Review. West Virginia Medical Journal, 120(2), 16. https://doi.org/10.21885/wvmj.2024.09
Vancouver
Radow M, MD, Morehead RS, MD. Hydralazine-Induced Vasculitis Causing Pulmonary-Renal Syndrome: Two Cases and a Literature Review. West Virginia Medical Journal. 2024;120(2):16. doi:10.21885/wvmj.2024.09
BibTeX
@article{Radow2024,
author = {Radow, Mark and MD and Morehead, R. Scott and MD},
title = {Hydralazine-Induced Vasculitis Causing Pulmonary-Renal Syndrome: Two Cases and a Literature Review},
journal = {West Virginia Medical Journal},
year = {2024},
volume = {120},
number = {2},
pages = {16},
doi = {10.21885/wvmj.2024.09}
}
EUVIMED